Ortho Tri-Cyclen Lo

See also: Generic Ortho Tri-Cyclen

Ortho Tri-Cyclen Lo is a brand name of ethinyl estradiol/norgestimate, approved by the FDA in the following formulation(s):

ORTHO TRI-CYCLEN LO (ethinyl estradiol; norgestimate - tablet; oral-28)

• 
  Manufacturer: JANSSEN PHARMS
  
  Approval date: August 22, 2002
  
  Strength(s): 0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG ^[RLD][AB]

Has a generic version of Ortho Tri-Cyclen Lo been approved?

A generic version of Ortho Tri-Cyclen Lo has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Ortho Tri-Cyclen Lo and have been approved by the FDA:

NORGESTIMATE AND ETHINYL ESTRADIOL (ethinyl estradiol; norgestimate tablet; oral-28)

• 
  Manufacturer: WATSON LABS
  
  Approval date: March 9, 2011
  
  Strength(s): 0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG ^[AB]

TRI LO SPRINTEC (ethinyl estradiol; norgestimate tablet; oral-28)

• 
  Manufacturer: BARR
  
  Approval date: June 29, 2009
  
  Strength(s): 0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ortho Tri-Cyclen Lo. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Triphasic oral contraceptive
  Patent 6,214,815
  Issued: April 10, 2001
  Inventor(s): Shangold; Gary & Rubin; Arkady & Upmalis; David
  Assignee(s): Ortho-McNeil Pharmaceuticals, Inc.
  A method of contraception in which an estrogen and a progestogen are administered daily in a three phase sequence for 21 days is disclosed. In the first phase a combination of an estrogen and a progestogen in a low but contraceptively effective daily dosage corresponding in estrogenic activity to 23-28 .mu.g of 17.alpha.-ethinylestradiol and in progestogenic activity to 0.065-0.75 mg of norethindrone is administered for 5-8 days; followed by the administering of the same dosage of estrogen and a progestogen corresponding in progestogenic activity to 0.25-1.0 mg of norethindrone for 7-11 days; followed by the administering of the same dosage of estrogen and a progestogen corresponding in progestogenic activity to 0.35-2.0 mg of norethindrone for 3-7 days; followed by 4-8 days without administering either an estrogen or a progestogen.
  
  Patent expiration dates:
  
  
  • June 9, 2019
    
    ✓ 
    Patent use: CONTRACEPTION
  
  
  
  • December 9, 2019
    
    ✓ 
    Pediatric exclusivity
  
  

See also...

• Ortho Tri-Cyclen Lo Consumer Information (Cerner Multum)
• Norgestimate and Ethinyl Estradiol Consumer Information (Wolters Kluwer)
• Ortho-Tri-Cyclen Consumer Information (Wolters Kluwer)
• Ethinyl estradiol and norgestimate Consumer Information (Cerner Multum)